scholarly journals Expression of Wnt/β-Catenin Signaling Pathway and Its Regulatory Role in Type I Collagen with TGF-β1 in Scleral Fibroblasts from an Experimentally Induced Myopia Guinea Pig Model

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Min Li ◽  
Ying Yuan ◽  
Qingzhong Chen ◽  
Rao Me ◽  
Qing Gu ◽  
...  

Background. To investigate Wnt/β-catenin signaling pathway expression and its regulation of type I collagen by TGF-β1 in scleral fibroblasts from form-deprivation myopia (FDM) guinea pig model.Methods. Wnt isoforms were examined using genome microarrays. Scleral fibroblasts from FDM group and self-control (SC) group were cultured. Wnt isoforms,β-catenin, TGF-β1, and type I collagen expression levels were examined in the two groups with or without DKK-1 or TGF-β1 neutralizing antibody.Results. For genome microarrays, the expression of Wnt3 in FDM group was significantly greater as confirmed in retinal and scleral tissue. The expression of Wnt3 andβ-catenin significantly increased in FDM group and decreased significantly with DKK-1. TGF-β1 expression level decreased significantly in FDM group and increased significantly with DKK-1. Along with morphological misalignment inside and outside cells, the amount of type I collagen decreased in FDM group. Furthermore, type I collagen increased and became regular in DKK-1 intervention group, whereas it decreased and rearranged more disorder in TGF-β1 neutralizing antibody intervention group.Conclusions. The activation of Wnt3/β-catenin signaling pathway was demonstrated in primary scleral fibroblasts in FDM. This pathway further reduced the expression of type I collagen by TGF-β1, which ultimately played a role in scleral remodeling during myopia development.

Lung ◽  
2009 ◽  
Vol 188 (2) ◽  
pp. 97-105 ◽  
Author(s):  
Paola Moreno-Alvarez ◽  
Edgar Sánchez-Guerrero ◽  
Erasmo Martínez-Cordero ◽  
Rogelio Hernández-Pando ◽  
María G. Campos ◽  
...  

npj Vaccines ◽  
2020 ◽  
Vol 5 (1) ◽  
Author(s):  
David I. Bernstein ◽  
Rhonda D. Cardin ◽  
Gregory A. Smith ◽  
Gary E. Pickard ◽  
Patricia J. Sollars ◽  
...  

Abstract Herpes simplex virus (HSV) infections are common and can cause severe illness but no vaccine is currently available. The recent failure of subunit HSV vaccines has highlighted the need for vaccines that present a diverse array of antigens, including the development of next-generation live-attenuated vaccines. However, most attenuated HSV strains propagate poorly, limiting their ability to elicit protective immune responses. A live-attenuated vaccine that replicates in non-neural tissue but is ablated for transmission into the nervous system may elicit protective immune responses without evoking neurologic complications or establishing life-long infections. Initial studies of R2, a live-attenuated vaccine that is engineered to be unable to invade the nervous system, used the guinea pig genital HSV model to evaluate the ability of R2 to replicate at the site of inoculation, cause disease and infect neural tissues. R2 was then evaluated as a vaccine using three routes of inoculation: intramuscular (IM), intradermal (ID) and intravaginal (IVag) and compared to IM administered gD2+MPL/Alum vaccine in the same model. R2 replicated in the genital tract but did not produce acute or recurrent disease and did not infect the neural tissue. The R2 vaccine-induced neutralizing antibody and decreased the severity of acute and recurrent HSV-2 disease as well as recurrent shedding. The ID route was the most effective. ID administered R2 was more effective than gD2+MPL/Alum at inducing neutralizing antibody, suppressing acute disease, and acute vaginal virus replication. R2 was especially more effective at reducing recurrent virus shedding, the most common source of HSV transmission. The live-attenuated prophylactic HSV vaccine, R2, was effective in the guinea pig model of genital HSV-2 especially when administered by the ID route. The use of live-attenuated HSV vaccines that robustly replicate in mucosal tissues but are ablated for neuroinvasion offers a promising approach for HSV vaccines.


2020 ◽  
Vol 09 (01) ◽  
Author(s):  
Novoselova EA ◽  
Alimbarova LM ◽  
Monakhova NS ◽  
Lepioshkin AY ◽  
Ekins S ◽  
...  

2021 ◽  
Vol 151 ◽  
pp. 104752
Author(s):  
Valerie E. Ryan ◽  
Taylor W. Bailey ◽  
Dongqi Liu ◽  
Tracy Vemulapalli ◽  
Bruce Cooper ◽  
...  

2011 ◽  
Vol 35 (4) ◽  
pp. 891-898 ◽  
Author(s):  
Matthew C. Fenty ◽  
George R. Dodge ◽  
Victor Babu Kassey ◽  
Walter R.T. Witschey ◽  
Arijitt Borthakur ◽  
...  

1999 ◽  
Vol 19 (8) ◽  
pp. 887-894 ◽  
Author(s):  
Yu-Ichiro Satoh ◽  
Kyoko Kasama ◽  
Mikiko Kuwabara ◽  
Hong-Yan Diao ◽  
Hirofumi Nakajima ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document